Association of calcium channel blocker use and pregnancy-associated plasma protein-A among older adults with hypertension: Results from the ilSIRENTE study

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 62, Issue 11, 2007, Pages 1274-1278

  Onder, Graziano ^a,b   Capoluongo, Ettore ^a   Cesari, Matteo ^a   Lulli, Paola ^a   Liperoti, Rosa ^a   Giardina, Bruno ^a   Russo, Andrea ^a   Bernabei, Roberto ^a   Landi, Francesco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; NIFEDIPINE; PREGNANCY ASSOCIATED PLASMA PROTEIN A; VERAPAMIL;

AGE DISTRIBUTION; AGED; ANALYSIS OF COVARIANCE; ARTICLE; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; ELDERLY CARE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX RATIO;

EID: 37349064776     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/62.11.1274     Document Type: Article

References (29)

1. Apple FS, Wu AH, Mair J, et al. Committee on Standardization of Markers of Cardiac Damage of the IFCC. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005;51:810-824.
2. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001;345:1022-1029.
3. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML, Zeiher AM; CAPTURE Study Investigators. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol. 2005;45:229-237.
4. Cosin-Sales J, Kaski JC, Christiansen M, et al. Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur Heart J. 2005;26:2093-2098.
5. Mueller T, Dieplinger B, Poelz W, Haltmayer M. Increased pregnancy-associated plasma protein-A as a marker for peripheral atherosclerosis: results from the Linz Peripheral Arterial Disease Study. Clin Chem. 2006;52:1096-1103.
6. Cosin-Sales J, Christiansen M, Kaminski P, et al. Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. Circulation. 2004;109:1724-1728.
7. Beaudeux JL, Burc L, Imbert-Bismut F, et al. Serum plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler Thromb Vasc Biol. 2003;23:e7-310.
8. Lund J, Qin QP, Ilva T, et al. Circulating pregnancy-associated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation. 2003;108:1924-1926.
9. Chobanian AV, Bakris GL, Black HR, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
10. Inzitari M, Di Bari M, Marchionni N. Calcium channel blockers and coronary heart disease. Aging Clin Exp Res. 2005;17(4 Suppl):6-15.
11. Roth M, Eickelberg O, Kohler E, Erne P, Block LH. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci U S A. 1996;93:5478-5482.
12. Ikeda U, Hojo Y, Ueno S, Arakawa H, Shimada K. Amlodipine inhibits expression of matrix metalloproteinase-1 and its inhibitor in human vascular endothelial cells. J Cardiovasc Pharmacol. 2000;35:887-890.
13. Landi F, Russo A, Cesari M, et al. The ilSIRENTE study: a prospective cohort study on persons aged 80 years and older living in a mountain community of Central Italy. Aging Clin Exp Res. 2005;17:486-493.
14. Morris JN, Fries BE, Bernabei R, et al. RAI-Home Care Assessment Manual. Washington, DC: InterRAI Coporation; 1996.
15. Morris JN, Fries BE, Steel K, et al. Comprehensive clinical assessment in community setting: applicability of the MDS-HC. J Am Geriatr Soc. 1997;45:1017-1024.
16. Hawes C, Morris JN, Phillips CD, Mor V, Fries BE, Nonemaker S. Reliability estimates for the Minimum Data Set for nursing home resident assessment and care screening (MDS). Gerontologist. 1995;35:172-178.
17. Landi F, Tua E, Onder G, et al. Minimum data set for home care: a valid instrument to assess frail older people living in the community. Med Care. 2000;38:1184-1190.
18. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin PU. Drug data coding and analysis in epidemiological studies. Eur J Epidemiol. 1994;10:405-411.
19. Onder G, Liperoti R, Russo A, et al. Body mass index, free insulin-like growth factor I, and physical function among older adults: results from the ilSIRENTE study. Am J Physiol Endocrinol Metab. 2006;291:E829-E834.
20. Khosravi J, Diamandi A, Krishna RG, Bodani U, Mistry J, Khaja N. Pregnancy associated plasma protein-A: ultrasensitive immunoassay and determination in coronary heart disease. Clin Biochem. 2002;35:531-538.
21. Conti E, Andreotti F, Zuppi C. Pregnancy-associated plasma protein A as predictor of outcome in patients with suspected acute coronary syndromes. Circulation. 2004;109:e211-e212.
22. Canavesi M, Baldini N, Leonardi A, Sironi G, Bellosta S, Bernini F. In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J Cardiovasc Pharmacol. 2004;44:416-422.
23. Yue H, Uzui H, Shimizu H, et al. Different effects of calcium channel blockers on matrix metalloproteinase-2 expression in cultured rat cardiac fibroblasts. J Cardiovasc Pharmacol. 2004;44:223-230.
24. Farias EF, Aguirre Ghiso JA, Ladeda V, Bal de Kier Joffe E. Verapamil inhibits tumor protease production, local invasion and metastasis development in murine carcinoma cells. Int J Cancer. 1998;78:727-734.
25. Godfraind T. Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Philos Trans R Soc Lond B Biol Sci. 2005;360:2259-2272.
26. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet. 1990;335:1109-1113.
27. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102:1503-1510.
28. Jorgensen B, Simonsen S, Endresen K, et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary Angioplasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol. 2000;35:592-599.
29. Zanchetti A, Bond MG, Hennig M, et al.; European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106:2422-2427.